Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response

Table 1 Baseline characteristics of patients (n = 238)

Continuous variables (mean ± SD)
Age (yr)	29 ± 8.5
Hemoglobin (g/dL)	11.49 ± 2.45
The mean platelet count (103/mm3)	145.6 ± 14.3
SGPT (IU/L)	134.18 ± 14.3
Hepatitis B DNA level (IU/mL)	155 × 103± 70.1 × 103
Categorical variable, frequency (%)
Sex
Male	180 (75.6)
Female	58 (24.4)
Stage of fibrosis
Stage 2	172 (72.3)
Stage 3	44 (18.5)
Stage 4	22 (9.2)
Biochemical response	122 (51.3)
End of treatment	71 (29.8)
Sustained viral response	70 (29.4)

SGPT: Serum glutamic pyruvic transaminase.

Table 2 Relation between biochemical response, end of treatment response and stage of fibrosis with sustained viral response n (%)

Variable	SVR achieved	SVR not achieved	P value
BR	60/122 (49.1)	62/122 (50.9)	0.001
ETR	70/71 (98.5)	1/71 (1.5)	0.001
Stage of fibrosis			0.002
Stage 2	39/172 (22.6)	133/172 (77.3)
Stage 3	18/44 (40.9)	26/44 (59.09)
Stage 4	13/22 (59)	9/22 (40.9)

SVR: Sustained viral response; BR: Biochemical response; ETR: End of treatment response.